<DOC>
	<DOC>NCT00184639</DOC>
	<brief_summary>This trial is conducted in Europe. A 32-week efficacy and safety comparison of insulin detemir and insulin semilente MC in children between 6 and 21 years with type 1 diabetes.</brief_summary>
	<brief_title>Comparison of Insulin Detemir and Insulin Semilente®MC in Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<criteria>Type 1 diabetes Current intensified insulin treatment Injection of insulin Semilente®MC at bedtime for at least 6 weeks BMI maximum 32 kg/m^2 HbA1c &gt; 5.5 % and &lt; 12.0 % Current treatment with premixed insulin(s) Impaired hepatic or renal function Recurrent major hypoglycaemia</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>